Details

Autor(en) / Beteiligte

• Feld, Jordan J
• Jacobson, Ira M
• Hézode, Christophe
• Asselah, Tarik
• Ruane, Peter J
• Gruener, Norbert
• Abergel, Armand
• Mangia, Alessandra
• Lai, Ching-Lung
• Chan, Henry L.Y
• Mazzotta, Francesco
• Moreno, Christophe
• Yoshida, Eric
• Shafran, Stephen D
• Towner, William J
• Tran, Tram T
• McNally, John
• Osinusi, Anu
• Svarovskaia, Evguenia
• Zhu, Yanni
• Brainard, Diana M
• McHutchison, John G
• Agarwal, Kosh
• Zeuzem, Stefan

Titel

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

Ist Teil von

• The New England journal of medicine, 2015-12, Vol.373 (27), p.2599-2607

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• In this phase 3 study involving patients with HCV genotype 1, 2, 4, 5, or 6 infection, including those with compensated cirrhosis, treatment with 12 weeks of sofosbuvir and velpatasvir resulted in a sustained virologic response in 99% of patients. The hepatitis C virus (HCV), a single-stranded RNA virus of the family Flaviviridae with six major genotypes, infects up to 150 million people worldwide. 1 , 2 Chronic HCV infection causes progressive liver fibrosis, which can lead to cirrhosis, hepatic decompensation, and hepatocellular carcinoma. 3 , 4 As many as half a million people die annually from liver disease associated with chronic HCV infection. 5 In recent years, the development of drugs that directly interfere with HCV replication has revolutionized HCV treatment. There are now effective combinations of direct-acting antiviral agents for most patients, but in choosing an appropriate regimen, clinicians must take into account . . .